Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
暂无分享,去创建一个
B. Beghé | E. Clini | S. Cerri | M. Dominici | A. Marchioni | R. Tonelli | A. V. Samarelli | G. Bruzzi | F. Gozzi | Dario Andrisani | I. Castaniere | L. Manicardi | A. Moretti | L. Tabbì | D. Andrisani
[1] E. Clini,et al. Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution , 2021, Frontiers in Pharmacology.
[2] C. Ryerson,et al. Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. , 2021, Clinics in chest medicine.
[3] Nan Tang,et al. Stem cells in pulmonary alveolar regeneration , 2021, Development.
[4] Mark G. Jones,et al. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2020, Pharmacology & therapeutics.
[5] Mario Silva,et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. , 2020, Clinical and experimental rheumatology.
[6] Toshihiro Ito,et al. Spred2-deficiency enhances the proliferation of lung epithelial cells and alleviates pulmonary fibrosis induced by bleomycin , 2020, Scientific Reports.
[7] M. Selman,et al. The Interplay of the Genetic Architecture, Aging, and Environmental Factors in the Pathogenesis of Idiopathic Pulmonary Fibrosis. , 2020, American journal of respiratory cell and molecular biology.
[8] M. Foley,et al. CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis , 2020, Respiratory Research.
[9] J. Catravas,et al. HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF) , 2020, International journal of molecular sciences.
[10] J. Verschakelen,et al. Desquamative interstitial pneumonia: a systematic review of its features and outcomes , 2020, European Respiratory Review.
[11] L. Richeldi,et al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis , 2020, Expert opinion on investigational drugs.
[12] J. Catravas,et al. Post-treatment with a heat shock protein 90 inhibitor prevents chronic lung injury and pulmonary fibrosis, following acute exposure of mice to HCl , 2020, Experimental lung research.
[13] M. Harlander,et al. Acute interstitial pneumonia triggered by strenuous exercise , 2020, Respiratory Medicine Case Reports.
[14] T. Corte,et al. Nonspecific Interstitial Pneumonia , 2020, Seminars in Respiratory and Critical Care Medicine.
[15] K. Brown,et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. , 2020, The Lancet. Respiratory medicine.
[16] M. Königshoff,et al. Chronic WNT/β-catenin signaling induces cellular senescence in lung epithelial cells. , 2020, Cellular signalling.
[17] C. Ryerson,et al. Progression of fibrosing interstitial lung disease , 2020, Respiratory Research.
[18] L. Ebner,et al. Meta-analysis of the radiological and clinical features of Usual Interstitial Pneumonia (UIP) and Nonspecific Interstitial Pneumonia (NSIP) , 2020, PloS one.
[19] M. Cho,et al. Genome-Wide Association Study: Functional Variant rs2076295 Regulates Desmoplakin Expression in Airway Epithelial Cells , 2020 .
[20] M. Kreuter,et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. , 2020, The Lancet. Respiratory medicine.
[21] C. Barber,et al. Identifying causation in hypersensitivity pneumonitis: a British perspective , 2019, BMJ Open Respiratory Research.
[22] M. Selman,et al. The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. , 2019, Cellular signalling.
[23] Seidai Sato,et al. Fibrocytes and Fibroblasts - where are we now. , 2019, The international journal of biochemistry & cell biology.
[24] S. Nava,et al. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. , 2019, Respiratory medicine.
[25] Xiaodong Han,et al. The Shh/Gli signaling cascade regulates myofibroblastic activation of lung-resident mesenchymal stem cells via the modulation of Wnt10a expression during pulmonary fibrogenesis , 2019, Laboratory Investigation.
[26] T. Corte,et al. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) , 2019, Drugs.
[27] J. Egen,et al. TAZ is required for lung alveolar epithelial cell differentiation after injury. , 2019, JCI insight.
[28] M. Ferrada,et al. Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management , 2019, Front. Immunol..
[29] Lin Chen,et al. Up-regulation of THY1 attenuates interstitial pulmonary fibrosis and promotes lung fibroblast apoptosis during acute interstitial pneumonia by blockade of the WNT signaling pathway , 2019, Cell cycle.
[30] V. Thannickal,et al. Developmental pathways in the pathogenesis of lung fibrosis. , 2019, Molecular aspects of medicine.
[31] M. Molina-Molina,et al. Interstitial Lung Diseases in Developing Countries , 2019, Annals of global health.
[32] J. Horowitz,et al. Mechanisms for the Resolution of Organ Fibrosis. , 2019, Physiology.
[33] G. Raghu,et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. , 2019, The Lancet. Respiratory medicine.
[34] Satoshi Noguchi,et al. YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer , 2018, International journal of molecular sciences.
[35] C. Nomura,et al. Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification , 2018, Radiologia brasileira.
[36] Takeshi Johkoh,et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.
[37] C. Howlett,et al. Comprehensive gene expression profiling identifies distinct and overlapping transcriptional profiles in non-specific interstitial pneumonia and idiopathic pulmonary fibrosis , 2018, Respiratory Research.
[38] N. Vaziri,et al. New insights into TGF-β/Smad signaling in tissue fibrosis. , 2018, Chemico-biological interactions.
[39] S. Dupont,et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. , 2018, The Lancet. Respiratory medicine.
[40] W. Seeger,et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis , 2018, Respiratory Research.
[41] B. Stripp,et al. Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. , 2018, JCI insight.
[42] T. Sugai,et al. Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias , 2018, Journal of immunology research.
[43] T. Sugai,et al. Distinct Profiles of CD 163-Positive Macrophages in Idiopathic Interstitial Pneumonias , 2018 .
[44] Yuan-jue Zhu,et al. Association between nonspecific interstitial pneumonia and presence of CD20+ B lymphocytes within pulmonary lymphoid follicles , 2017, Scientific Reports.
[45] Melanie E Moses,et al. ROCK regulates the intermittent mode of interstitial T cell migration in inflamed lungs , 2017, Nature Communications.
[46] A. Shilatifard,et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span , 2017, The Journal of experimental medicine.
[47] K. Meyer. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis , 2017, Expert review of respiratory medicine.
[48] A. Jegga,et al. Hsp90 regulation of fibroblast activation in pulmonary fibrosis. , 2017, JCI insight.
[49] W. Seeger,et al. Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. , 2017, Cell stem cell.
[50] M. Kolb,et al. Heat shock protein: a hot topic in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.
[51] W. Seeger,et al. Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. , 2017, Cell stem cell.
[52] B. Stripp,et al. Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. , 2016, JCI insight.
[53] S. Gharib,et al. Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. , 2016, The American journal of pathology.
[54] T. Panchabhai,et al. Lymphocytic Interstitial Pneumonia. , 2016, Clinics in chest medicine.
[55] P. Chambon,et al. Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. , 2016, The Journal of clinical investigation.
[56] D. Lynch,et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.
[57] Y. Kondoh,et al. Acute and subacute idiopathic interstitial pneumonias , 2016, Respirology.
[58] D. Thickett,et al. Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis , 2016, BMC Pulmonary Medicine.
[59] A. Ryan,et al. Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis. , 2016, Immunity.
[60] S. Zucker,et al. Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts , 2016, Respiratory Research.
[61] K. Flaherty,et al. Idiopathic non‐specific interstitial pneumonia , 2016, Respirology.
[62] S. Harari,et al. Smoking‐related idiopathic interstitial pneumonia: A review , 2016 .
[63] P. Chambon,et al. Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. , 2016, The Journal of clinical investigation.
[64] M. Kreuter,et al. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives , 2015, BioMed research international.
[65] S. Bellusci,et al. Evidence for the involvement of fibroblast growth factor 10 in lipofibroblast formation during embryonic lung development , 2015, Development.
[66] S. Shin,et al. Inflammatory Diseases of the Lung Induced by Conventional Cigarette Smoke: A Review. , 2015, Chest.
[67] D. Lynch,et al. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.
[68] Alexander Pautsch,et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.
[69] C. Redlich,et al. Asbestosis and environmental causes of usual interstitial pneumonia , 2015, Current opinion in pulmonary medicine.
[70] H. Binder,et al. Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis , 2015, PloS one.
[71] J. Liao,et al. The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis , 2015, Pharmacological Reviews.
[72] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.
[73] Athol U. Wells,et al. Interstitial lung disease in connective tissue disease—mechanisms and management , 2014, Nature Reviews Rheumatology.
[74] S. Menon,et al. ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. , 2014, American journal of physiology. Cell physiology.
[75] Buqu Hu,et al. Chitinase 3–Like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis , 2014, Science Translational Medicine.
[76] C. Vancheri,et al. Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review , 2014, Insights into Imaging.
[77] Xiaozhi Wang,et al. Alveolar epithelial cells undergo epithelial-mesenchymal transition in acute interstitial pneumonia: a case report , 2014, BMC Pulmonary Medicine.
[78] Joyce S Lee,et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. , 2014, Chest.
[79] V. Thannickal,et al. Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[80] K. Ichikado. High-resolution computed tomography findings of acute respiratory distress syndrome, acute interstitial pneumonia, and acute exacerbation of idiopathic pulmonary fibrosis. , 2014, Seminars in ultrasound, CT, and MR.
[81] S. Rosselot. Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[82] M. Andrianifahanana,et al. Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[83] J. Bates,et al. Stem cells and cell therapies in lung biology and diseases: conference report. , 2013, Annals of the American Thoracic Society.
[84] W. Altemeier,et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. , 2013, American journal of respiratory and critical care medicine.
[85] F. Bonella,et al. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. , 2013, Respiratory medicine.
[86] Y. Moodley,et al. Anti-Inflammatory Effects of Adult Stem Cells in Sustained Lung Injury: A Comparative Study , 2013, PloS one.
[87] E. Ansó,et al. Matrix Metalloproteinase (MMP)-1 Induces Lung Alveolar Epithelial Cell Migration and Proliferation, Protects from Apoptosis, and Represses Mitochondrial Oxygen Consumption* , 2013, The Journal of Biological Chemistry.
[88] A. Oikonomou,et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis , 2013, Journal of Translational Medicine.
[89] L. Ortiz,et al. Cell therapy trials for lung diseases: progress and cautions. , 2013, American journal of respiratory and critical care medicine.
[90] M. Glassberg,et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. , 2013, American journal of respiratory and critical care medicine.
[91] B. Ghanim,et al. Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. , 2013, Journal of proteomics.
[92] Cynthia Davidson,et al. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. , 2012, American journal of respiratory cell and molecular biology.
[93] T. Colby,et al. Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients , 2012, BMC Pulmonary Medicine.
[94] S. Glaser,et al. General mechanisms of nicotine‐induced fibrogenesis , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[95] A. Fabre,et al. The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. , 2012, The American journal of pathology.
[96] M. Gaxiola,et al. Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. , 2012, American journal of physiology. Lung cellular and molecular physiology.
[97] B. Hinz. Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. , 2012, Proceedings of the American Thoracic Society.
[98] J. Massagué. TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.
[99] N. Sverzellati,et al. An integrated approach in the diagnosis of smoking-related interstitial lung diseases , 2012, European Respiratory Review.
[100] I. Rosas,et al. Autophagy in Idiopathic Pulmonary Fibrosis , 2012, PloS one.
[101] Konstantinos Karagiannis,et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. , 2012, International journal of oncology.
[102] Michael J. Cronce,et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition , 2011, Proceedings of the National Academy of Sciences.
[103] S. Sahn,et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.
[104] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .
[105] D. Guinee. Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities. , 2010, Archives of pathology & laboratory medicine.
[106] M. Armanios. Syndromes of telomere shortening. , 2009, Annual review of genomics and human genetics.
[107] G. Raghu,et al. Telomere shortening in familial and sporadic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.
[108] Athol Wells,et al. Idiopathic nonspecific interstitial pneumonia: Report of an American thoracic society project , 2008 .
[109] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[110] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[111] P. Lansdorp,et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.
[112] D. Sheppard,et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.
[113] Naftali Kaminski,et al. Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis , 2005, PLoS medicine.
[114] David A Lynch,et al. Idiopathic interstitial pneumonias: CT features. , 2005, Radiology.
[115] K. Kuwano,et al. The p53–Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia , 2005, Journal of Clinical Pathology.
[116] A. Nicholson,et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. , 2005, The American journal of pathology.
[117] Dorsett D. Smith. Diagnosis and Initial Management of Nonmalignant Diseases Related to Asbestos , 2003 .
[118] N. Siafakas,et al. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. , 2005, Chest.
[119] M. Burdick,et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.
[120] Gerald J Berry,et al. Lymphoid interstitial pneumonia: a narrative review. , 2002, Chest.
[121] H. Ihn. Pathogenesis of fibrosis: role of TGF-β and CTGF , 2002 .
[122] Koichiro Yoshida,et al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis , 2002, The Journal of pathology.
[123] Jonathan Haines,et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. , 2002, American journal of respiratory and critical care medicine.
[124] A. Nicholson,et al. Reactive pulmonary lymphoid disorders , 1995, Histopathology.
[125] K. Adler,et al. The myofibroblast in pulmonary fibrosis. , 1983, Chest.